全球糖尿病治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計抗糖尿病藥物的市場規模將從 2025 年的 982.3 億美元成長到 2034 年的 2,140.6 億美元，2026 年至 2034 年的複合年成長率為 9.04%。

全球糖尿病盛行率的不斷上升正顯著推動全球抗糖尿病藥物市場的成長。久坐不動的生活方式、不健康的飲食習慣以及日益嚴重的肥胖問題等因素，都導致了糖尿病患者人數的增加。這使得人們對有效控制血糖值和預防併發症的藥物的需求日益成長。

關鍵成長要素包括藥物研發的進步，例如創新胰島素療法和口服降血糖藥。聯合治療和個人化治療方案的日益普及也推動了市場擴張。此外，人們對糖尿病管理的日益關注以及政府為改善醫療服務可近性而採取的措施也促進了市場需求。

持續的研發投入可望推動市場發展，進而催生更有效、更便捷的治療方案。血糖值監測設備和行動醫療應用等數位健康技術的整合將進一步改善患者的治療效果。隨著全球糖尿病負擔的不斷加重，預計未來幾年抗糖尿病藥物市場將保持持續成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球糖尿病治療市場：依產品分類

• 市場分析、洞察與預測
• 胰島素
• 快速起效
• 長效型
• 預混合料胰島素
• 短效

第5章 全球糖尿病治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 雙胍類藥物
• GLP-促效劑
• 胰島素增敏劑
• 磺醯尿素類藥物
• SGLT-2
• α-Glucosidase酶抑制劑
• DPP-4抑制劑
• Meglitinides類藥物

第6章 全球糖尿病藥物市場：依患者群體分類

• 市場分析、洞察與預測
• 兒童
• 成人
• 老年人

第7章 全球糖尿病治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射
• 靜脈
• 胰島素幫浦
• 胰島素筆/注射器

第8章 全球糖尿病治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Halozyme Therapeutics
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc
  • Sanofi SA
  • Oramed Pharmaceuticals
  • Novo Nordisk
  • Merck & Co. Inc
  • Novartis AG

The Antidiabetics Market size is expected to reach USD 214.06 Billion in 2034 from USD 98.23 Billion (2025) growing at a CAGR of 9.04% during 2026-2034.

The global antidiabetics market is experiencing significant growth due to the rising prevalence of diabetes worldwide. Factors such as sedentary lifestyles, unhealthy diets, and increasing obesity rates are contributing to the growing number of diabetic patients. This has led to a higher demand for effective medications to manage blood glucose levels and prevent complications.

Major drivers include advancements in drug development, including innovative insulin therapies and oral antidiabetic drugs. The increasing adoption of combination therapies and personalized treatment approaches is also supporting market expansion. Additionally, growing awareness about diabetes management and government initiatives to improve healthcare access are boosting demand.

Looking ahead, the market is expected to benefit from continuous research and development, leading to more effective and convenient treatment options. The integration of digital health technologies, such as glucose monitoring devices and mobile health applications, will further enhance patient outcomes. As the global burden of diabetes continues to rise, the antidiabetics market is set for sustained growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Insulin
• Rapid Acting
• Long Acting
• Premixed Insulin
• Short Acting

By Drug Class

• Biguanides
• GLP-Agonists
• Thiazolidinediones
• Sulphonylureas
• SGLT-2
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• Meglitinides

By Patient Population

• Pediatric
• Adults
• Geriatric

By Route of Administration

• Oral
• Infusion
• Intravenous
• Insulin Pumps
• Insulin Pen/Syringes

COMPANIES PROFILED

• Eli Lilly and Company, , Boehringer Ingelheim, BristolMyers Squibb Company, Pfizer Inc, Halozyme Therapeutics, AstraZeneca Plc, Bayer AG, Johnson Johnson Services Inc, Sanofi SA, Oramed Pharmaceuticals, Novo Nordisk, Merck Co Inc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIDIABETICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Rapid Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Long Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Premixed Insulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Short Acting Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIDIABETICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Biguanides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. GLP-Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Sulphonylureas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. SGLT-2 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Alpha-Glucosidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. DPP-4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Meglitinides Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIDIABETICS MARKET: BY PATIENT POPULATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Population
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adults Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIDIABETICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Infusion Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Insulin Pumps Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Insulin Pen/Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIDIABETICS MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Drug Class
  • 8.2.3 By Patient Population
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Drug Class
  • 8.3.3 By Patient Population
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Drug Class
  • 8.4.3 By Patient Population
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Drug Class
  • 8.5.3 By Patient Population
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Drug Class
  • 8.6.3 By Patient Population
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ANTIDIABETICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Boehringer Ingelheim
  • 10.2.2 Bristol-Myers Squibb Company
  • 10.2.3 Pfizer Inc
  • 10.2.4 Halozyme Therapeutics
  • 10.2.5 AstraZeneca Plc
  • 10.2.6 Bayer AG
  • 10.2.7 Johnson & Johnson Services Inc
  • 10.2.8 Sanofi S.A
  • 10.2.9 Oramed Pharmaceuticals
  • 10.2.10 Novo Nordisk
  • 10.2.11 Merck & Co. Inc
  • 10.2.12 Novartis AG